Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Intrathecal DepoCyte and Lineage-Targeted Minimal Residual Disease-Oriented Therapy of Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 65				Other				NILG-ALL 10/07 NCT00795756


2.		DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2005-0135 NCT00515788

Last Modified: 11/7/2008 First Published: 11/20/2003


3.		Phase II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				BIDMC-2003P-000182 NCT00073957

Last Modified: 11/24/2008 First Published: 10/21/2006


4.		Phase II Study of Rituximab, Cyclophosphamide, Vincristine, Doxorubicin Hydrochloride, and High-Dose Methotrexate (R-CODOX-M) Alone or Alternating With Rituximab and Ifosfamide, Etoposide Phosphate, and High-Dose Cytarabine (IVAC) in Combination With Intrathecal CNS Prophylaxis in Patients With Newly Diagnosed, HIV-Associated Burkitt's or Atypical Burkitt's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				AMC-048 AMC-048, NCT00392834


5.		Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				2004-004414-17 DEPOCYLAN, NCT00388531


6.		Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-Cell Lymphoma With Neuromeningeal Invasion at Diagnosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 60				Other				R-C5R 2006 R-C5R, NCT00553943


7.		High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				19 to 65				Other, Pharmaceutical / Industry				SCNSL1 IIL-SCNSL-1, NCT00801216

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute